Reuters logo
BRIEF-EMA paediatric committee agrees to Albireo's A4250 pediatric investigation plan
September 26, 2017 / 12:28 PM / 3 months ago

BRIEF-EMA paediatric committee agrees to Albireo's A4250 pediatric investigation plan

Sept 26 (Reuters) - Albireo Pharma Inc:

* EMA’s paediatric committee agrees to Albireo’s a4250 pediatric investigation plan

* Albireo Pharma - ‍completion of pip would provide an additional two years of market exclusivity​

* Albireo Pharma - ‍plan to initiate our previously announced phase 3 trial of A4250 by year end​

* Albireo Pharma - pdco of EMA agreed to pediatric investigation plan for lead product candidate a4250 in patients with pfic

* Albireo Pharma Inc - ‍completion of agreed pip would provide an additional two years of market exclusivity in EU, making a total of 12 years​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below